China's EV71 inactivated vaccine against HFMD has entered the final stage of evaluation

Wang Lifeng, director of CFDA pharmaceutical and chemical department, introduced at a press conference on the morning of July 4 that the clinical trials of EV71 inactivated (Vero cell) vaccine for the prevention of HFMD in China have been completed in succession, and it has entered the stage of production registration review At present, it has entered the final stage of review, and will soon be on the market "If you come out now, it will be the first EV71 vaccine in the world." Hand, foot and mouth disease (HFMD) is a kind of children's infectious disease, which mostly occurs in children under 5 years old It can cause herpes in hands, feet, mouth and other parts A few children can cause complications such as myocarditis, pulmonary edema, aseptic meningoencephalitis, etc if the disease develops rapidly, some severe children will die HFMD is often caused by enterovirus EV71 infection, and there is no corresponding vaccine at home and abroad HFMD vaccine belongs to one of the varieties with urgent domestic demand and great market potential At present, there are not a few enterprises involved in R & D The research and development leaders are domestic micro Valley biomedicine (belonging to Zhongsheng Co., Ltd.), Kexing Biology (NASDAQ: SVA) and Institute of medical biology of Chinese Academy of Medical Sciences (Kunming Institute), which have successively applied for the production approval of the vaccine; Kexing biology and Zhongsheng Co., Ltd even started to prepare supporting production workshops and GMP certification in the second half of last year In addition, Hualan biology also declared the clinical application of adsorption inactivated vaccine (Vero cell) for HFMD (EV71) in February last year.